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Abstract
Aim The main aim of this study was to examine the
effectiveness of rectoscopy for detecting local recurrence
of rectal cancer in patients following low anterior resec-
tion.
Method This was a retrospective study of 201 patients,
who underwent low anterior resection for rectal or rec-
tosigmoid cancer between 2007 and 2009 and who were
followed up with rigid rectoscopy and imaging. A total of
91 patients were excluded from the analysis for various rea-
sons, leaving 110 patients eligible for analysis.
Results A total of 613 rectoscopies were performed,
and 48 biopsies taken. Six local recurrences were
detected in the 110 patients, three of which were first
detected by rectoscopy and three by CT. Two of the
local recurrences were detected outside the follow-up
programme because of symptoms: one by rectoscopy
and one by CT. Three of 613 (0.5%) rectoscopies led
to detection of local recurrence. The sensitivity and
specificity of rectoscopy to detect local recurrence was
0.50 and 0.93, respectively. Nineteen distant metastases
were detected, and two patients had both local recur-
rence and distant metastasis. All local recurrences and
distant metastases were detected within 48 months of
surgery.
Conclusion Rigid rectoscopy is poor at detecting local
recurrence. Only 3 out of 613 rectoscopies (0.5%)
detected local recurrence. Due to extramural growth
of some recurrences, the sensitivity is also very low.
Based on our results, routine rectoscopy in the surveil-
lance of asymptomatic patients cannot be recom-
mended.
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What does this paper add to the literature?
Systematic follow-up after rectal cancer surgery is wide-
spread, but documentation regarding follow-up recto-
scopies is scarce. This study suggests that rectoscopy is
unreliable at detecting recurrence and cannot be recom-
mended as routine practice.
Introduction
Colorectal cancer is one of the most commonly diag-
nosed cancers in men and women, with 1325 new cases
of rectal or rectosigmoid cancer in 2017 in Norway.
The 5-year survival rate has increased over the last dec-
ades, being 68.9% and 69.4% in the period 2013–2017
for women and men, respectively [1]. Over the same
time period the incidence of local recurrence has also
decreased. Today, the estimated 5-year local recurrence
rate for Stage I–III patients operated on in Norway in
the period 2015–2017 is 3.4% [1]. About 30–60% of
local recurrences grow outside the lumen and are not
visible by rectoscopy [2]. Despite common practice,
there is little evidence that intensive follow-up pro-
grammes improve survival compared with minimal or
no follow-up [3].
According to the Norwegian national guidelines, fol-
low-up after low anterior rectal resection is conducted
by the surgeon and comprises rigid rectoscopy every
6 months for the first 3 years and every 12 months for
the following 2 years (Table 1) [4]. Rectoscopy is con-
sidered a relatively easy and cheap examination,
although patients may experience pain, discomfort and
anxiety [5]. However, the effectiveness of rectoscopy in
detecting local recurrence after surgery for rectal malig-
nancy has not been studied.
The main aim of this study was to examine the effec-
tiveness of rectoscopy in detecting local recurrence after
surgery for rectal cancer.
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Method
Patient population and exclusion criteria
All patients who underwent surgery for rectal cancer
with an anastomosis less than 15 cm from the anal
verge between 2007 and 2009 at the Haukeland
University Hospital, Norway were included. All patients
were examined preoperatively by rectoscopy using a
rigid scope. Rectosigmoid cancer was defined as tumour
less than 20 cm from the anal verge. A total of 91 out
of the initial 201 patients were excluded (Fig. 1).
Follow-up protocol
The Norwegian follow-up protocol is shown in Table 1.
In addition to measurement of serum carcinoembryonic
antigen (CEA) and radiological examinations, the fol-
low-up comprises digital rectal examination and rigid
rectoscopy every 6 months for the first 3 years and
every 12 months for the following 2 years. At
60 months postoperatively, a colonoscopy is also
included. According to the guidelines, patients are sup-
posed to be followed up for 60 months. For various
reasons, some of the patients had either a shorter or a
longer follow-up. Data from all follow-ups at the surgi-
cal outpatient clinic were collected even if they occurred
after the recommended 60-month postoperative follow-
up period.
Rectoscopies and imaging procedures were registered
as belonging to the same follow-up appointment if they
occurred within a timeframe of 2 months. This meant
that many patients ended up having more than the rec-
ommended eight follow-up appointments as there were
regularly more than 2 months between rectoscopy and
radiological imaging. Consultations consisting only of
information concerning pathology postoperatively,
anamnesis, CEA measurement or general clinical exami-
nation without rectoscopy or imaging were not consid-
ered as oncological follow-up appointments. Patients
receiving colonoscopy were registered in the database,
but no further analysis was carried out.
The reference value for CEA levels was defined as
the first postoperative value available, and all following
measurements were compared with this. A significant
elevation of CEA was defined as a three-fold increase
relative to the postoperative value [4].
Statistics
Data from the electronic patient record (DIPSTM ASA,
Bodø, Norway) were registered and analysed by SPSS
version 23 (SPSS, Chicago, Illinois, USA). As many as
15 consecutive follow-ups have been registered per
patient. Sensitivity and specificity for rectoscopy were
calculated using a contingency table. A true positive was
defined as local recurrence detected by rectoscopy on
routine follow-up and confirmed by biopsy. Local recur-
rences detected by CT or MRI, and not rectoscopy,
were defined as false negatives with respect to rec-
toscopy. In evaluating the effectiveness of rectoscopy we
calculated the total number of examinations that needed
to be performed to detect a single recurrence.
Ethics
The regional ethics committee (REK) in Bergen, Nor-
way approved this study.
Results
Patient characteristics
Characteristics of the study population are shown in
Table 2. Postoperative complications according to
tumour classification are in Table 3. Patients not eligible
for follow-up were older, suffered from a higher rate of
comorbidity and were more often classified as American
Society of Anesthesiologists (ASA) group III (data not
shown).
Table 1 Norwegian guidelines for follow-up [6].
Postoperative month 1 6 12 18 24 30 36 48 60
CEA x x x x x x x x
CT liver/abdomen/pelvis x x
Liver US with contrast x x x x x x
Low-dose CT thorax x x x x x
Colonoscopy x
Rectal examination x x x x x x x x
Tumour > 20 cm from anal verge.
CEA, carcinoembryonic antigen; US, ultrasound.
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Number of local recurrences
Six out of 110 patients (5.5%) were diagnosed with
local recurrence during the observation period; four of
these were detected at routine follow-up appointment,
of which two were first detected with CT scan and two
by rectoscopy (Table 4). None of the patients with local
recurrence detected at routine follow-up reported symp-
toms prior to examination. One of the patients who
had the recurrence detected by rectoscopy had a CT
scan performed at the same time which did not reveal
the recurrence. Another patient had the local recurrence
detected by CT scan, later confirmed by MRI. This
patient did not undergo rectoscopy in the follow-up,
and we have no information about intraluminal tumour
growth or whether the tumour could be visible during
rectoscopy. Furthermore, two recurrences were detected
outside the follow-up programme in patients admitted
to hospital, one with rectal bleeding (local recurrence
detected by rectoscopy) and the other with pulmonary
embolism (local recurrence detected by CT scan and
confirmed by rectoscopy). Only one of the patients with
local recurrence had a serum CEA measured at the same
follow-up as the recurrence was detected, but the value
measured was not significantly increased. Hence five out
of six patients with local recurrence underwent rec-
toscopy.
The histological features found in Table 3 were anal-
ysed for their ability to predict local recurrence. A micro-
scopically positive circumferential margin (CRM; R1,
tumour growth < 1 mm of the CRM) was found in six
patients. None of these developed tumour recurrence.
The distal resection margin was defined as ´narrow´ when
tumour was detected within 5 mm. We found that five of
the six patients with local recurrence had a narrow or pos-
itive distal resection margin. Of the 86 patients who did
not develop recurrent cancer, three had a positive and
eight a narrow distal resection margin. The sensitivity of a
narrow distal resection margin of less than 5 mm was
33.3% (95% CI 11.8–61.6), specificity 92.0% (95% CI
83.4–97.1), diagnostic accuracy of positive R narrow
being 82.2% (95% CI 72.7–89.5).
Rectoscopy and biopsy outcome
There were 48 biopsies (7.8%) taken in the 613 recto-
scopies performed, of which 43 were reported as benign




Serious complications before 
follow-up (16)
174













Figure 1 Patient exclusion.
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outside regular follow-up. One of the local recurrences
detected in routine follow-up was detected by CT prior
to rectoscopy. No convincing suspect tumour lesions
were detected by rectoscopy; however, biopsy was taken
because of the CT description. For this reason, this
biopsy was not counted as ‘pathology seen in rec-
toscopy’ when calculating sensitivity and specificity but
as ‘normal rectoscopy’ (Table 5). The sensitivity and
specificity of rectoscopies to detect local recurrence are
calculated to be 0.50 and 0.93, respectively (the two
local recurrences detected outside regular follow-up are
not included). The numbers used in this calculation are
shown in Table 5.
Technical difficulties in performance of rectoscopy
Some patients were not prepared adequately for rec-
toscopy upon arrival at the appointment, making the
examination impossible or inconclusive. Additionally,
patients with stenotic anastomosis or abscesses left the
examination inconclusive with regard to recurrence.
Imaging and CEA
In addition to the local recurrences 19 distant metas-
tases were detected, eight by CT scan, seven by chest
X-ray and/or liver ultrasound and four by CEA mea-
surements. Six of 617 CEA measurements (1.0%) were
significantly elevated, two leading to detection of metas-
tasis and two revealing metastases at CT scan on the
same follow-up (defined as detected by CT scan in this
paper); the last two had no metastasis despite the eleva-
tion in CEA. Two metastases were detected after ele-
vated, nonsignificant values. None of the patients with
local recurrences had a raised CEA.
Table 2 Patient characteristics.
Number
(percentage)*
Gender (M:F ratio) 1.56
Age (years), median (range) 62.0 (21–84)
BMI (kg/m2)
Underweight (< 18.5) 2 (1.8)
Normal (18.5–25) 44 (40.0)
Overweight (> 25) 59 (53.6)














Anastomosis < 5 cm
Yes 21 (19.1)
No 82 (74.5)
Missing data 7 (6.4)
Anastomosis level (cm), mean (SD) 7.1 (3.1)
*Except where stated otherwise.
ASA, American Society of Anesthesiologists; BMI, body mass
index.











Stoma reversal 51 (46.4)
Metastasis/recurrence 19 (17.3)
Acute complications 21 (19.1)
Other 8 (7.3)
Residual tumour
Distal margin ≥ 5 mm 93 (84.5)
Distal margin 0–4 mm/uncertain margin 12 (10.1)
Circumferential resection margin < 1mm 6 (3.0)












Tumour not found 8 (7.3)
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Time of follow-up
Follow-up appointments were based on guideline rec-
ommendations. Figure 2 shows the number of follow-
up appointments for each month postoperatively, rang-
ing from 0 to 90 months, with vertical lines marking
the recommended times for follow-up in months.
Patients who experienced complications or had a
temporary stoma started follow-up later than recom-
mended. A total of 931 follow-ups were registered, giv-
ing 821 intervals. The mean interval length is
5.87 months and 188 intervals were exactly 6 months
long. Twenty out of 110 patients had their first follow-
up later than 6 months after operation. Eighty-four of
110 patients attended the final follow-up at 60-months.
Discussion
The main aim of this study was to evaluate the effective-
ness of rectoscopy in surveillance after rectal cancer sur-
gery. The adoption of national surveillance guidelines is
time-consuming. Even though rectoscopies are recom-
mended on every follow-up from 6 to 60 months after
operation, only a maximum of 75% of the patients at
any given time during follow-up were examined by rec-
toscopy. Only 5 out of 48 biopsies taken were malig-
nant, and only three of these were taken on regular
follow-up appointments. Our findings suggest that rec-
toscopy is poor at detecting local recurrence. These
findings are in agreement with the only other study on
the subject, in which rectoscopy failed to diagnose the
one local recurrence in 112 patients [5].
Our results do not permit any conclusions to be drawn
on the significance of presenting symptoms. Only one
patient in this study experienced bleeding due to recur-
rence of cancer. Therefore, we cannot conclude on whether
the presence of symptoms is a better indication for rec-
toscopy than a routine rectoscopy of all patients. It is possi-
ble that patient discomfort deters patients from repeated
rectoscopy. The examination is usually, but not invariably,
well tolerated [6]. We recognize that flexible sigmoi-
doscopy is better tolerated than rigid rectoscopy [7].
Over the 5 years of follow-up in the present study
we have observed a trend away from X-rays and ultra-
sonography towards CT scans. This probably reflects
increased reliance on CT imaging, and the fact that
national guidelines suggest CT scan as an alternative if
contrast-enhanced ultrasound is not available [4].
Table 4 Local recurrences.
Patient number Months after operation Modality Symptoms Comment
1 11 CT Confirmed by DRE and biopsy taken 1 month after CT
scan. CEA not measured at time of recurrence
2 40 CT Confirmed by MRI. CEA value not significantly increased.
No rectoscopy
3 7 Rectoscopy CEA not measured at time of recurrence. No CT









CT Admitted to hospital with pulmonary embolism.
Recurrence suspected on CT confirmed by rectoscopy.
Unknown CEA value
CEA, carcinoembryonic antigen; DRE, digital rectal examination.
Table 5 Sensitivity and specificity of rectoscopy in routine follow-up.
Sensitivity 0.50
Specificity 0.93
PPV 0.04 No recurrence Local recurrence Sum
NPV 0.99 Normal rectoscopy 564 2 566
Accuracy 0.93 Pathology seen in rectoscopy 43 2 45
Likelihood 7.14 Sum 607 4 611
NPV, negative predictive value; PPV, positive predictive value.
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Imaging (CT scan, chest X-ray and abdominal ultra-
sound) detected 15 out of 19 metastases. Additionally,
imaging was used to confirm metastases in the remain-
ing four patients with elevated CEA values. The use of
CT scan in follow-up to detect local recurrence is fur-
ther supported by the fact that local recurrence with
extraluminal involvement has become the most preva-
lent pattern after the introduction of total mesorectal
excision [8]. In a study conducted by Rahbari et al. [9],
62.0% of the local recurrences were located extralumi-
nally. In another study by Kusters et al. [10], only
22.9% of local recurrences were in the proximity of the
anastomosis. We still recommend digital rectal examina-
tion and rectoscopy in symptomatic patients as these
procedures are simple and will detect obvious recur-
rence. Extraluminal recurrence, on the other hand, can-
not be detected by rectoscopy and in some cases can
also be difficult to detect by endoscopic ultrasound and
CT. In our institution, we perform MRI in these cases.
In our study, one of the local recurrences was detected
by rectoscopy and not by CT. However, CT remains a
method of choice since it can detect distant metastasis in
addition to local recurrence. Most of the recurrences occur
during the first 3 years and affect the liver, lymph nodes,
lung and peritoneum, and no fewer than 20% of metastases
occur during the first 3 months after diagnosis [11].
Therefore, annual CT of thorax, abdomen and pelvis for
the first 3 years after surgery can be recommended.
Our data show a higher risk of local recurrence
among patients with a distal resection margin of less
than 5 mm. Based on these findings, this subgroup of
patients could benefit from a closer follow-up, including
clinical examination and rectoscopy by the surgeon.
A close distance of the tumour to the CRM has also
been shown to be a strong and independent risk factor
for local recurrence. An involved CRM of < 1 mm car-
ries the highest risk for local recurrence with a hazard
ratio of 4.4 [12] in mid rectal cancer. However, in the
present study none of the patients with CRM < 1 mm
developed a local recurrence [13].
In this retrospective study, information about why
patients left the programme, had the start of follow-up
delayed or had more appointments than recommended
is not available. Another issue concerns patient compli-
ance with follow-up, especially towards the end of the
programme. Only 76% of patients attended to the last
follow-up. The number of patients leaving the follow-
up programme was higher than in other similar studies
[14–16]. The present study revealed a low compliance
with follow-up and large differences in the number of
and intervals between follow-up appointments.
Further studies are necessary to measure the effective-
ness of surveillance programmes for patients treated for
rectal cancer. In the present surveillance protocol, rec-
toscopy is not effective. Future studies should also address
the ability of rectoscopy to detect local recurrence [17].
Traditional follow-up programmes focus primarily on
the detection of recurrence and less on late effects and
quality of life. A recent study from Denmark investi-
gated a more patient-centred follow-up, with an
increased focus on physiological and psychological out-
comes. The hypothesis is that patient-led follow-up will
enable identification and treatment of adverse events
and lead to earlier detection of local recurrence [18].
A close nurse-guided follow-up embedded in a
symptom-orientated postcancer care programme may be
more helpful for patients from all necessary perspectives
and better accepted. In specialized hands it could be
more effective and efficient, restricting routine recto-
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Figure 2 Number of patients at follow-up appointments 0–90 months after operation. Vertical lines mark the recommended times
for follow-up according to national guidelines [6].
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Conclusion
Routine rigid rectoscopy has a low sensitivity to detect
local recurrences and is not efficient. There is an evident
difference from scheduled follow-up appointments as
recommended by national guidelines regarding time
point and frequency, and there are a high number of
dropouts from the programme within a 5-year follow-
up period. This results in a relatively high number of
patients going without surveillance. CT scan seems to
be more appropriate for detecting extraluminal recur-
rence and distant metastasis. Rectoscopy cannot be rec-
ommended as routine part of a follow-up programme.
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